FIGURE
FIGURE 1
- ID
- ZDB-FIG-210327-80
- Publication
- Chung et al., 2021 - Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models
- Other Figures
- All Figure Page
- Back to All Figure Page
FIGURE 1
Summary of patient treatment. Before the development of malignant ascites, the patient received three lines of anti‐HER2 treatment for metastatic disease and following disease progression. FEC, fluorouracil, epirubicin, and cyclophosphamide; TH, docetaxel and trastuzumab; PD, progressive disease |
Expression Data
Expression Detail
Antibody Labeling
Phenotype Data
Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and
ZFIN has permission only to display this image to its users.
Additional permissions should be obtained from the applicable author or publisher of the image.
Full text @ Cancer Med